BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT
A recent approach for limiting production of pro-inflammatory cytokines has been to target bromodomain and extra-terminal (BET) proteins. These epigenetic readers of histone acetylation regulate transcription of genes involved in inflammation, cardiovascular disease, and cancer. Development of BET i...
Main Authors: | Sabrina N. Copsel, Casey O. Lightbourn, Henry Barreras, Ines Lohse, Dietlinde Wolf, Cameron S. Bader, John Manov, Brandon J. Kale, Devangi Shah, Shaun P. Brothers, Victor L. Perez, Krishna V. Komanduri, Claes Wahlestedt, Robert B. Levy |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.03104/full |
Similar Items
-
Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection
by: Casey O. Lightbourn, et al.
Published: (2021-03-01) -
Recipient Tregs: Can They Be Exploited for Successful Hematopoietic Stem Cell Transplant Outcomes?
by: Sabrina N. Copsel, et al.
Published: (2022-06-01) -
Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients
by: Jessica L. Dennison, et al.
Published: (2022-08-01) -
Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma.
by: Ines Lohse, et al.
Published: (2018-01-01) -
Systematic pan-cancer analysis identifies gasdermin B as an immunological and prognostic biomarker for kidney renal clear cell carcinoma
by: Xuehe Liu, et al.
Published: (2023-03-01)